|
For immediate release |
29 July 2024 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Result of AGM
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions except resolutions 16 and 17, as set out in the Notice of Meeting, were duly passed on a poll.
The number of the Group's shares in issue as at the date of the meeting was 540,565,539 ordinary shares of 1p each*.
The votes were as follows:
|
RESOLUTION |
VOTES FOR |
% |
VOTES AGAINST |
% |
VOTES WITHHELD |
|
|
1 |
Report and Accounts |
190,733,158 |
99.99 |
14,451 |
0.01 |
12,870 |
|
2 |
Approve Remuneration Report |
118,424,151 |
62.09 |
72,319,389 |
37.91 |
16,939 |
|
3 |
Elect C. Pane |
167,821,883 |
99.34 |
1,108,987 |
0.66 |
21,829,609 |
|
4 |
Elect R. McKenzie |
190,719,135 |
99.98 |
28,979 |
0.02 |
12,365 |
|
5 |
Elect EL. Sjostedt |
190,672,019 |
99.96 |
76,095 |
0.040 |
12,365 |
|
6 |
Elect N. Sedgwick |
190,708,640 |
99.98 |
38,979 |
0.020 |
12,860 |
|
7 |
Re-elect A. Franklin |
190,546,663 |
99.89 |
201,451 |
0.11 |
12,365 |
|
8 |
Re-elect J. Heper (Withdrawn) |
- |
- |
- |
- |
- |
|
9 |
Re-elect R. Jones |
119,208,411 |
62.55 |
71,381,969 |
37.45 |
170,099 |
|
10 |
Re-elect K. Neirynck |
190,554,413 |
99.98 |
36,462 |
0.02 |
169,604 |
|
11 |
Re-elect M. Sutherland |
119,879,952 |
62.90 |
70,710,923 |
37.10 |
169,604 |
|
12 |
Appointment of Auditor |
190,656,799 |
99.95 |
90,085 |
0.05 |
13,595 |
|
13 |
Remuneration of Auditor |
190,715,105 |
99.98 |
32,274 |
0.02 |
13,100 |
|
14 |
Allot shares - general |
119,812,913 |
62.81 |
70,933,841 |
37.19 |
13,725 |
|
15 |
Allot shares - additional |
120,008,767 |
62.92 |
70,735,963 |
37.08 |
15,749 |
|
16 |
Disapply pre-emption rights - general |
119,970,667 |
62.90 |
70,776,712 |
37.10 |
13,100 |
|
17 |
Disapply pre-emption rights - additional |
119,912,206 |
62.86 |
70,835,173 |
37.14 |
13,100 |
The Board notes the votes against Resolutions 2, 9, 11, 14, 15, 16 and 17 and will consult with shareholders to understand their views and publish the results of that consultation in due course.
Chris Chrysanthou
Group General Counsel & Company Secretary
29 July 2024
*Each share carries one vote and a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.
For further information:
|
Alliance Pharma plc |
+ 44 (0)1249 466966 |
|
Cora McCallum, Head of Investor Relations & Corporate Communications |
+ 44 (0)1249 705168 |
|
|
|
|
|
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
|
Mark Court / Sophie Wills |
|
|
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint Broker) |
+ 44 (0)20 7260 1000 |
|
Freddie Barnfield / Duncan Monteith / Sher Shah |
|
|
|
|
|
Investec Bank plc (Joint Broker) |
+ 44 (0)20 7597 5970 |
|
Patrick Robb / Ben Lawrence / Maria Gomez de Olea |
|
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
